FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washin

gton, D.C. 20549	Ī

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Hayes Melvin H. III</u>					2. Issuer Name and Ticker or Trading Symbol Fulcrum Therapeutics, Inc. [FULC]						(Ch	eck all applic Director	able)	ng Person(s) to Issuer 10% Owne Other (spec		ner
(Last) (First) (Middle) C/O FULCRUM THERAPEUTICS, INC. 26 LANDSDOWNE STREET					3. Date of Earliest Transaction (Month/Day/Year) 02/09/2023							below)	nief Opera	below)	Jeony	
(Street) CAMBRIDGE MA 02139 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
1. Title of Security (Instr. 3) 2. Transa Date			ransactio			Code (Instr. 8)		red (A) or str. 3, 4 and	5. Amour	es Form ally (D) o following (I) (Ir		Direct Ir ndirect B r. 4) C	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Table II - Der (e.g						posed o	f, or Ber	eficially	(Instr. 3 a	nd 4)			
1. Title of Derivative Security (Instr. 3)	Conversion Date Execution Date, Trai		Transa Code (5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)			10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	лі(э)		
Stock Option (right to buy)	\$12.59	02/09/2023		A		135,000		(1)	02/08/2033	Common Stock	135,000	\$0.00	135,000	0	D	

Explanation of Responses:

1. This option was granted on February 9, 2023 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2023, subject to the reporting person's continued service on each such vesting date.

Remarks:

/s/ Gregory Tourangeau, as attorney-in-fact for Melvin

02/13/2023

Hayes

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.